Business Wire

PA-SYNERGIS-SOFTWARE

Share
Synergis Adept Named #1 in 21 Rankings on G2’s 2020 Fall Grid Reports

Synergis Software , a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd ’s Fall 2020 Grid Reports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005422/en/

The reports, which are based on real customer reviews, highlight Adept’s leadership in ease of use, ease of setup, fastest implementation, best support and best relationship as some of the key differentiators compared to other products on the market.

Adept earned Leader status in Product Data Management (PDM) and Enterprise Content Management (ECM), and High Performer status in Construction Drawing Management.

“We're committed to helping clients become more efficient, secure and collaborative, and reports like this help us understand what we're doing well and how we can improve,” said Scott Lamond, vice president of marketing at Synergis Software. “We’re energized and honored that the voice of the customer has us ranked at the top of our field.”

Adept also achieved an exceptional 77 on the G2 Net Promoter Scorecard (NPS).

According to G2, “The purpose of NPS is to gauge customer loyalty to a brand, and how likely they are to recommend your product to a peer. An NPS at-or-above 70 is considered “world class.” Essentially, this means nearly every customer would advocate for that product."

Here’s what some Adept customers had to say:

  • “Data is the cornerstone of any business today and not securing it is a huge risk. If you want to do it right and do it well, the Adept platform is the gold-standard.”
  • “No other software company anywhere works as closely with their customers. For a system that your business cannot operate without, this is invaluable.”
  • “An immediate 30% gain in user efficiency”

Adept earned top honors in the following rankings:

Product Data Management - Best Usability, Easiest Setup, Fastest Implementation, Most Implementable, Ease of Administration, Ease of Doing Business, Quality of Support, Best Relationship, Most Likely to Recommend, Highest Net Promoter Score

Construction Drawing Management - Easiest to Use, Best Meets Requirements, Easiest Setup, Best Support, Highest User Adoption, Easiest to do Business With, Product Going in the Right Direction, Most likely to Recommend, Highest Net Promoter Score

Enterprise Content Management - Ease of Doing Business With, Best Search Capabilities

To see how Adept stacks up, download the full comparison report .

You can read more customer feedback on G2’s Adept review page .

Learn more about G2’s scoring methodology here .

About Synergis Software

Synergis Software is the leader in engineering document management and product data management, helping businesses become more efficient, secure and collaborative. The flagship product, Adept, gets everyone on the same page, simplifying the way organizations find, manage, share and integrate enterprise content. Adept streamlines engineering change management, protects intellectual property, and provides data insights to improve decision making. Adept is integrated with AutoCAD®, Autodesk Inventor®, SolidWorks® and MicroStation®, and has been battle tested by engineers for over 30 years in customers like Dow Chemical, Con Edison, General Mills, Bayer, and Nucor Steel.

G2 Crowd

G2 Crowd , the world's leading business solution review platform, leverages more than 790,000 user reviews to drive better purchasing decisions. G2 aims to bring authenticity and transparency to the business marketplace by leveraging peer reviews, satisfaction scores, and synthesized social data.

Link:

ClickThru

Social Media:

https://www.facebook.com/synergissoftware/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye